Department of Medicine, Shandong University School of Medicine, Jinan, Shandong, 250014, P. R. China.
Cardiovascular Medicine Department, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China.
Rev Cardiovasc Med. 2020 Mar 30;21(1):57-64. doi: 10.31083/j.rcm.2020.01.577.
Cardiovascular disease is still the main cause of morbidity and mortality worldwide. Currently, the frontier of research into cardiovascular disease is the field of non-coding RNA. In this review, information was collected on the use of micro-RNAs as non-invasive biomarkers and their role in pathophysiological processes and therapeutic applications. In the case of microRNA-1 and microRNA-133, the roles and regulatory mechanisms of them are reviewed for arrhythmia, myocardial infarction, diabetic cardiomyopathy, myocardial hypertrophy, cardiomyocyte differentiation, and cell reprogramming. It was observed that microRNA-1 and microRNA-133 do not exist independently, but are two co-transcriptional and cooperative regulatory factors. They have diagnostic value as biomarkers, but also have the potential as therapeutic targets such as for antiarrhythmia and cardiac reprogramming.
心血管疾病仍然是全球发病率和死亡率的主要原因。目前，心血管疾病研究的前沿领域是非编码 RNA 领域。在这篇综述中，收集了关于 microRNA 作为非侵入性生物标志物的应用及其在病理生理过程和治疗应用中的作用的信息。在 microRNA-1 和 microRNA-133 的情况下，综述了它们在心律失常、心肌梗死、糖尿病心肌病、心肌肥厚、心肌细胞分化和细胞重编程中的作用和调节机制。观察到 microRNA-1 和 microRNA-133 并非独立存在，而是两个共转录和协同调节因子。它们具有作为生物标志物的诊断价值，但也具有作为抗心律失常和心脏重编程等治疗靶点的潜力。
